13 reports of this reaction
2.2% of all GLYBURIDE AND METFORMIN HYDROCHLORIDE reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for GLYBURIDE AND METFORMIN HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 13 FDA adverse event reports linking GLYBURIDE AND METFORMIN HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.2% of all 579 adverse event reports for this drug.
Patients taking GLYBURIDE AND METFORMIN HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for GLYBURIDE AND METFORMIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for GLYBURIDE AND METFORMIN HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 13 FDA reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking GLYBURIDE AND METFORMIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.